34 results about "Recombinant virus" patented technology

Nucleotide compositions, recombinant vectors, and recombinant viral genomes are disclosed that include a modified horseradish peroxidase (HRP) gene sequence, as well as recombinant viruses that have the modified HRP gene sequence incorporated into the viral genome thereof. The recombinant viruses are utilized in an HRP-based assay to analyze the neutralization potential of candidate antiviral agents, such as antiviral antibodies.

The application discloses an African swine fever virus attenuated strain with I215L protein deletion, a live vaccine preparation method and application thereof, and belongs to the technical field of biotechnology, and particularly relates to an African swine fever virus attenuated strain with I215L protein deletion, a live vaccine preparation method and application thereof. The recombinant virus prepared by the application is an African swine fever virus I215L protein function deletion strain, the I215L partial gene is deleted, and the immunization of the weak strain with the gene deletion can achieve 100% immune protection effect on homologous II type ASFV and heterologous I / II type ASFV, and meanwhile, there is no residue in the body, so that the application has a wide application prospect.

Herein is reported a method for separating recombinant viral particles from other compounds of a mammalian cell culture broth comprising the steps of adding a silica-based filter aid like diatomaceous earth (DE) or synthetic silica-based filter aid to a mammalian cell culture broth comprising recombinant viral particles at a weight ratio of more than 1:2 DE or synthetic silica-based filter aid / biological wet mass (BWM) to obtain a pre-filtration mixture and subjecting the pre-filtration mixture to alluvial filtration, whereby recombinant viral particles are separated from other compounds of the mammalian cell culture broth.

This invention provides improved compositions and methods for mRNA display libraries for the rapid production of stable recombinant high-affinity binders. [Solution] A composition, method, and use of recombinant viruses and / or recombinant viral vectors encoding distinct antibodies or antibody fragments prepared from a highly diverse nucleic acid library are disclosed. Preferably, the recombinant virus is a genetically modified low immunogenic virus, for example, an E2b deletion adenovirus. The highly diverse nucleic acid library is (1)V H -CDR1 / 2 sublibrary, (2) multiple V H -CDR3 sublibrary and (3)V L It includes or is derived from sublibraries, each of which includes multiple members. Preferably, each member of the sublibrary includes at least one random cassette having multiple degenerate base positions.

Provided is a recombinant adeno-associated virus (rAAV) or recombinant lentivirus, comprising an expression cassette in the genome, the expression cassette comprises a polynucleotide encoding thiamine pyrophosphokinase (TPK), which is operatively linked to a promoter. Also provided are also a pharmaceutical composition comprising the rAAV or recombinant lentivirus, and use of the rAAV, recombinant lentivirus and the pharmaceutical composition in the preparation of a medicament for treating or preventing Alzheimer's disease.

Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.

To provide methods for characterizing a preparation of recombinant viral particles for monitoring drug product quality with regard to homogeneity, purity and consistency of manufacturing.SOLUTION: A method of characterizing a preparation of recombinant viral particles comprises the steps of: a) subjecting the preparation to analytical ultracentrifugation under boundary sedimentation velocity conditions, wherein the sedimentation of recombinant viral particles is monitored at time intervals; b) plotting differential sedimentation coefficient distribution value (C(s)) versus sedimentation coefficient in Svedberg units (S); and c) integrating areas under respective peaks in the C(s) distribution to determine a relative concentration of each peak, wherein each peak represents a species of recombinant viral recombinant viral particle.SELECTED DRAWING: None

The present invention provides recombinant viral vectors containing and expressing antigens of avian pathogens, compositions comprising said recombinant viral vectors, and polyvalent vaccines comprising them. The present invention also provides methods for vaccination against various avian pathogens and a method for producing the recombinant viral vectors.

This invention relates to the field of agricultural biotechnology, and in particular to... Sr10618 Genes and their encoded proteins, their application in regulating resistance to white mold disease in peppers, primer pairs, recombinant viral silencing vectors and methods. Related factors in pepper plant resistance to white mold disease. Sr10618 The nucleotide sequence of the gene is shown in SEQ ID NO.1. Sr10618 The amino acid sequence of the protein encoded by the gene is shown in SEQ ID NO.2. A method for improving the resistance of pepper plants to white mold disease is also provided, including silencing the white mold pathogen effector. Sr10618 The expression of the gene in pepper plants, the Sr10618 The nucleotide sequence of the gene is shown in SEQ ID NO.1. (The above...) Sr10618 The application of genes and their encoded proteins, amplification primer pairs, recombinant silencing vectors, and methods to improve the resistance of pepper plants to white mold disease can regulate the resistance of pepper plants to white mold disease.

This invention relates to mutants of the adeno-associated virus (AAV) capsid protein. Recombinant viral vectors carrying mutants of the AAV1 capsid protein can be used for the specific expression of the introduced gene in astrocytes at the site of spinal cord injury lesions.

This disclosure relates to adeno-associated virus variants capable of performing astrocyte-specific gene transfer. Administration of a recombinant viral vector containing nucleic acid encoding an AAV capsid protein mutant according to this disclosure enables the transfer and expression of therapeutic genes into specific astrocytes, thus demonstrating significant efficacy in the prevention or treatment of brain diseases.

The present invention relates to oncolytic vaccinia viruses and recombinant viruses and methods of use thereof. In particular, the present invention provides a cloned vaccinia virus strain exhibiting enhanced anti-tumor properties and / or reduced immunogenicity, as well as a recombinant vaccinia virus derived therefrom. The present invention also provides recombinant oncolytic virus strains comprising an inactivated mutation in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses (e.g., vaccinia viruses, including recombinant vaccinia viruses) provided herein are useful as oncolytic viral therapies (e.g., oncolytic vaccinia viral therapies) for the treatment of cancer. The invention also provides pharmaceutical compositions of the virus, such as vaccinia virus, and methods and uses of the virus, such as vaccinia virus, for the treatment of cancer, as well as nucleic acids encoding the virus.

This invention relates to oncolytic vaccinia viruses, recombinant viruses thereof, and methods of use. Specifically, the invention provides vaccinia virus clone lines and recombinant vaccinia viruses derived therefrom, said vaccinia virus clone lines exhibiting enhanced antitumor properties and / or reduced immunogenicity. The invention also provides recombinant oncolytic virus lines comprising inactivating mutations in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses provided by this invention (such as vaccinia viruses, including recombinant vaccinia viruses) can be used as oncolytic virus therapies (such as oncolytic vaccinia virus therapy) for the treatment of cancer. The invention also provides pharmaceutical compositions of viruses (such as vaccinia viruses), methods and uses of viruses (such as vaccinia viruses) for the treatment of cancer, and nucleic acids encoding said viruses.

Provided are a capsid-modified adeno-associated virus (AAV), preparation therefor and a use thereof. Specifically, provided are an AAV capsid protein variant, a preparation method for recombinant AAV particles comprising a variant capsid protein, and compared with an AAV containing an unmodified parental AAV capsid protein, increased infectivity and gene product expression thereof in target cells such as retinal cells.

Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and / or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus strains that include an inactivating mutation in one or more viral genes, and / or one of more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses, e.g., vaccinia viruses, provided herein, including recombinant vaccinia viruses, can be used as an oncolytic virus therapy, e.g., an oncolytic vaccinia virus therapy, for treating cancer. Also provided herein are pharmaceutical compositions and methods and uses of the viruses, e.g., vaccinia viruses, for treating cancer, as well as nucleic acids encoding the viruses.

This invention belongs to the field of viral genetic engineering technology and discloses a bovine herpesvirus type 1 (BHV-1) with three gene deletions, its construction method, and its applications. Using a Fosmid library, four myxovirus rescue combinations were screened. FosBHV-1-b-ΔTK-mCherry and FosBHV-1-d-ΔgEct / US9-eGFP were obtained through Red / ET and Gateway methods. These were then combined with FosBHV-1-a and FosBHV-1-c to construct an infectious cloning platform for recombinant BHV-1 with the TK / gEct / US9 three-gene deletions, rescuing recombinant viruses carrying tracer genes. This method has high recombination efficiency, and the cloning platform can efficiently construct BHV-1 gene-deleted strains. The immunogenicity of the deleted strains is comparable to that of wild-type viruses, with good safety, providing an efficient technical means for the development of BHV-1 attenuated vaccines and bovine disease live vector vaccines.

Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.

A polynucleotide is provided comprising a nucleotide sequence encoding a biomolecule (e.g., human α-galactosidase A), a nucleotide sequence encoding a promoter (e.g., a hepatocyte-specific promoter or a hepatocyte-myocyte dual-specific promoter), or a nucleotide sequence encoding an expression cassette (e.g., a human α-galactosidase A expression cassette). Furthermore, promoters, expression cassettes, vectors, host cells, gene delivery systems (e.g., recombinant adeno-associated virus (AAV) particles and recombinant viral particles such as nonviral gene delivery systems), related pharmaceutical compositions, and methods for using them are also provided. Such compositions and methods are particularly suitable for gene therapy, and especially for lysosomal storage disorders, including Fabry disease.

The present invention relates to a polypeptide that induces ribbon synapse formation in the inner ear or increases the number of ribbon synapses in the inner ear, or improves the function of ribbon synapses. The present invention also relates to a polypeptide having the ability to promote neurite outgrowth or increase branch points of spiral ganglion neurons. A pharmaceutical composition comprising a polypeptide, a nucleic acid molecule encoding the polypeptide, a vector comprising the nucleic acid molecule, recombinant viral particles comprising the vector and a capsid protein, a cell comprising the vector, a cell transformed with the vector, or a combination thereof, of the present invention, prevents or ameliorates damage to or abnormality of the auditory system or the equilibrium system (vestibular system), and thus can be effectively used as a therapeutic agent for inner ear diseases.

The present invention relates to the field of biological vaccine research and development technology, and in particular, to a VSV vector-based highly pathogenic H5 subtype avian influenza inactivated vaccine and a method for preparing same. The method comprises: using a vesicular stomatitis virus with the deletion of the surface envelope protein gene as a vector, inserting the NA gene and the HA gene of an H5 subtype highly pathogenic avian influenza virus strain between the M gene and the L gene of the vector in the form of an expression cassette, and acquiring a recombinant virus by means of rescue via reverse genetic technology; inoculating the recombinant virus into susceptible cells, culturing for replication and proliferation, and then harvesting a viral solution; inactivating the viral solution to acquire an inactivated viral solution; and adding the inactivated viral solution to a pharmaceutically or veterinarily acceptable carrier, excipient, medium, or adjuvant to acquire an inactivated vaccine. The provided H5 subtype avian influenza inactivated vaccine can induce a high hemagglutination inhibition titer of avian influenza virus on day 21 after chick immunization. The provided inactivated vaccine has good safety and immunogenicity.

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a gasdermin. The invention is further directed to the use of the recombinant virus in the treatment of cancer and also to methods for producing such viruses.

This invention discloses a linearized mutant plasmid of Tembusu virus SLII, a recombinant virus, and its applications, belonging to the field of molecular biology. Using the pACNR CQW1-Intron infectious clone as a backbone, the SLII stem-loop structure within the 3′UTR Domain-I region was linearized to construct the SLII linearized mutant infectious clone pACNR-CQW1-SLIILiner, which was then rescued to obtain the recombinant virus CQW1-SLIILiner. This recombinant virus exhibits limited replication capacity at the in vitro cellular level and displays a significantly attenuated phenotype in animal models. It can also induce specific neutralizing antibodies and cellular immune responses, providing significant protection against virulent strains. Therefore, the recombinant virus of this invention possesses advantages such as clear molecular genetic markers, high safety, good immunogenicity, and strong genetic stability, and can be applied to the preparation of live attenuated vaccines or related biological products for the prevention of TMUV infection.

The disclosure relates generally to methods of producing recombinant viral vectors with reduced immunogenicity.

This invention provides a method for characterizing recombinant viral particle preparations using analytical ultracentrifugation. The recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenovirus particles, recombinant lentivirus particles, and recombinant herpes simplex virus particles. Different variants of recombinant viral particles, including empty capsids and recombinant viral particles with different genomes (e.g., truncated genomes, aggregates, recombinants), can be identified and quantified. This method can be used to characterize recombinant viral particle preparations regardless of the genomic sequence of the recombinant virus or the serotype of the recombinant viral capsid.

The present invention provides gene therapy plasmids and transgenes comprising soluble tissue non-specific alkaline phosphatase, recombinant virus vectors for delivery of said viral plasmids and transgenes and medical uses relating to the treatment of pyrophosphate deposition diseases and / or hypophosphatasia.

Described herein are nucleic acids and recombinant viral vectors comprising said nucleic acids, wherein said nucleic acids comprise an interferon that is regulated by alternative splicing.

Nucleic acids and recombinant viral vectors containing said nucleic acids are described herein, wherein the said nucleic acids encode a target payload (e.g., interferon).

Immunogenic compositions comprising hemagglutinin (HA) variants and / or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.